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Abstract Sulfatases are members of a highly conserved family
of enzymes that catalyze the hydrolysis of sulfate ester bonds
from a variety of substrates. The functional correlation reflects a
high degree of amino acid sequence similarity along the entire
length, in particular in the active site where the C(X)PSR
consensus sequence is present. Cysteine undergoes an important
co- or post-translation modification essential for the accomplish-
ment of catalytic activity: conversion in formylglycine. In this
work, the cysteine of heparan N-sulfatase (NS) was replaced
either by a serine (C70S) or by a methionine (C70M) using site-
directed mutagenesis. C70S and C70M mutant cDNAs were
expressed and analyzed in COS cells ; both mutations caused a
loss of NS activity; however, while C70S showed a normal
precursor form undergoing processing to a reduced mature form
within the lysosomes, C70M was poorly synthesized and formed
a complex with the molecular chaperone immunoglobulin binding
protein. ß 2001 Federation of European Biochemical Soci-
eties. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Heparan N-sulfatase (NS, EC 3.10.1.1) is a lysosomal en-
zyme involved in the degradation of heparan sulfate; the de-
¢ciency of this enzyme [1,2] results in mucopolysaccharidosis
type IIIA (MPS-IIIA), an autosomal recessive disorder char-
acterized by clinical severity [3]. The full-length cDNA and
genomic sequences for human NS have been isolated and
characterized [4,5] ; the NS gene is located on chromosome
17q25.3. Molecular analysis performed in MPS-IIIA patients
allowed the identi¢cation of a large variety of alterations, with
some prevalent mutations and several other defects providing
evidence for clinical heterogeneity [6^9]. In humans, NS has
been characterized in di¡erent tissues as a 56 kDa polypeptide
[10]; the recombinant NS protein is synthesized in the rough
endoplasmic reticulum (RER) as a 62 kDa glycosylated pre-
cursor protein that is targeted through Golgi and processed in
the vacuolar network until it reaches the lysosomes, where it is
detected as a 56 kDa mature glycoprotein [11,12]. The se-
quence contains ¢ve putative N-glycosylation sites, which we
have recently demonstrated to be all functional, with Asn41
and Asn151 having a role in the protein folding and/or stabil-
ity [13].
NS is a member of an evolutionary conserved gene family
that hydrolyze sulfate ester bonds from a variety of substrates
including glycosaminoglycans, glycolipids and steroids. Eleven
mammalian sulfatases have been identi¢ed: DNA alterations
on eight of these cause distinct human disorders. Mutations
a¡ecting sulfatases responsible for mucopolysaccharidoses
have recently been reviewed [14]. The homology of the sulfa-
tase sequence is striking, especially in the N-terminal region,
where the active site characterized by the conserved amino
acid sequence C(X)PSR is located [15]. Besides sequence ho-
mology, sulfatases also share a unique post-translational mod-
i¢cation that converts the conserved cysteine into formylgly-
cine in the endoplasmic reticulum [16]. The lack of this
modi¢cation leaves newly synthesized sulfatases inactive and
is the cause of multiple sulfatase de¢ciency (MSD), a rare but
fatal lysosomal storage disorder where all sulfatase activities
are severely decreased despite normal processing [17]. Crystal-
lographic analysis has demonstrated the structural similarity
of the sulfatases and con¢rmed that the conserved cysteine
residue is part of the catalytic site [18].
In this study, we produced by site-directed mutagenesis in
vitro two NS mutant cDNAs in which the highly conserved
cysteine was replaced either by a serine or by a methionine;
each recombinant mutant cDNA was transfected in COS cells
and analyzed for the NS enzymatic activity and biosynthesis.
We show that position 70 is critical for enzyme activity and
processing: the C70S mutant protein is secreted in the me-
dium, processed to the mature form in the lysosomes but is
partially degraded; the C70M mutant protein is not secreted
and forms a complex with BiP, an immunoglobulin heavy
chain binding protein.
2. Materials and methods
2.1. Site-directed mutagenesis
NS cDNA mutants were generated by site-directed mutagenesis
using the Transformer II kit (Clontech) according to the manufactur-
er’s instructions.
To introduce the mutations C70S and C70M, the following oligo-
nucleotides were used: 5P (CTCGGTCAGCAGCAGCTCTCCCA-
GCCGCGC, C70S); 5P (CTCGGTCAGCAGCATGTCTCCCAGC-
CGCGC, C70M).
0014-5793 / 01 / $20.00 ß 2001 Federation of European Biochemical Societies. Published by Elsevier Science B.V. All rights reserved.
PII: S 0 0 1 4 - 5 7 9 3 ( 0 1 ) 0 2 8 6 7 - 8
*Corresponding author. Fax: (39)-081-7463150.
E-mail address: daniele@cds.unina.it (A. Daniele).
Abbreviations: MPS-IIIA, mucopolysaccharidosis type IIIA; NS,
heparan N-sulfatase; wt, wild-type; BiP, immunoglobulin binding
protein; RER, rough endoplasmic reticulum
FEBS 25266 14-9-01
FEBS 25266 FEBS Letters 505 (2001) 445^448
2.2. Transfection procedure, NS and L-galactosidase activity
measurements, Western blot analysis, metabolic labeling,
reverse transcriptase-PCR (RT-PCR)
The conditions for these procedures have been previously reported
[9].
2.3. Association of NS proteins to BiP
Forty eight hours after transfection, COS cells in 6 cm plates con-
taining wild-type (wt) or mutant cDNA constructs were immunopre-
cipitated with 2 Wl anti-NS antibody. The immunoprecipitated pro-
teins were denatured, separated by 10% SDS^PAGE and transferred
to nitrocellulose ¢lters (Bio-Rad). The membranes were treated with a
monoclonal antibody recognizing BiP (Grp94 and Grp78) used at a
1:500 dilution in TBS with 1% dry milk; the antibody immunopreci-
pitates also an aspeci¢c protein of 40 kDa (SPA-827, StressGen, Can-
ada). Visualization of antibody binding was carried out with ECL
(Amersham Pharmacia Biotech).
3. Results
3.1. Enzyme activity of NS Cys mutants
In the NS protein, the cysteine at position 70 is one of the
amino acid components of the C(X)PSR motif, part of the
catalytic site and conserved within the sulfatase family. To
investigate the importance of this residue in the NS protein,
we generated by site-directed mutagenesis two mutated NS
cDNAs in which the cysteine codon (Cys) was converted
into a methionine (Met) or serine (Ser) codon, respectively.
Wt and mutant expression plasmids were transiently co-trans-
fected with L-galactosidase cDNA into COS cells by electro-
poration. After 48 h, the total cell extracts and the culture
medium were analyzed for NS activity. The results are shown
in Table 1: the untransfected COS cells (negative control)
showed a residual activity of 4.9 nmol/17 h/mg; the COS cells
transfected with the wt NS cDNA had an activity of 58.3
nmol/17 h/mg, i.e. a 12-fold increase. Cells expressing C70S
and C70M mutants exhibited a drastic reduction in the cata-
lytic activity, 7.8 and 8.6 nmol/17 h/mg, respectively. These
results demonstrated that the mutations in the cysteine 70
residue resulted in a strong decrease in the catalytic activity
of the NS enzyme, presumably as a consequence of an impair-
ment of the normal function of the active site.
3.2. Western blot analysis
The presence of mutated NS polypeptides in transfected
COS cell extracts was tested by immunoblot analysis using
anti-NS antibody. In cells expressing the NS wt cDNA, two
bands were visualized relating to the precursor (62 kDa) and
the mature form (56 kDa) of the enzyme. Results comparable
to wt were found in cells transfected with the C70S mutation
(Fig. 1). In contrast, in cells transfected with C70M mutant
cDNA, the precursor was signi¢cantly reduced, while the ma-
ture form was not detectable (Fig. 1), indicating that it was
subjected to rapid degradation.
3.3. Metabolic labeling of normal and mutated NS protein
The biosynthetic pathway of wt and cysteine mutants was
examined by pulse-chase labeling experiments; radioactivity
incorporated into NS was determined after immunoprecipita-
tion and separation by SDS^PAGE. The results are shown in
Fig. 2. In COS cells transfected with wt NS, a precursor form
of 62 kDa was evident after a 2 h pulse labeling that was
converted into the 56 kDa mature lysosomal form or secreted
Fig. 1. Western blot analysis. 30 Wg of total extracts of cells trans-
fected with the NS wt and Cys mutant cDNA constructs was sub-
jected to SDS^PAGE, followed by immunoblotting with anti-NS
antiserum (1:500). M: molecular mass standards in kDa.
Fig. 2. Metabolic labeling of NS wt and Cys mutants. COS cells,
transfected with the NS wt and Cys mutant cDNA constructs, were
labeled for 2 h (pulse) and harvested after a subsequent 24 h chase
period. NS polypeptides were immunoprecipitated from the media
(M) or from cell pulse (C1), and cell chase (C2), separated by SDS^
PAGE and detected by autoradiography. The arrows on the right
indicate the NS 62 kDa precursor and the 56 kDa mature forms.
Molecular mass markers are indicated on the left.
Fig. 3. Immunoblot recognizing BiP protein. Wt and Cys mutant
COS cell extracts were immunoprecipitated with polyclonal anti-NS
antiserum, then the denatured immunoprecipitates were resolved in
10% SDS gel and transferred onto the nitrocellulose membrane. BiP
was detected by immunoblotting with an antibody recognizing
Grp94 and Grp78; the antibody identi¢es, arrow on the right, also
an aspeci¢c protein of 40 kDa (see Section 2).
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into the culture medium. C70S mutant cDNA, transfected in
COS cells, encodes a protein with a similar precursor form of
the enzyme (either in the medium or in the cells) ; however, a
reduction was observed in the mature form to approximately
40% of the wt, as indicated by densitometric analysis of the
bands (Fig. 2). Conversely, in cells expressing C70M cDNA,
the NS protein was poorly synthesized with minute amounts
of precursor form and no mature form within the cells ; no
precursor form was visible in the culture medium (Fig. 2).
3.4. Synthesis of C70S and C70M mRNAs in vitro
RT-PCR experiments were performed to examine if a tran-
script was present in the cells transfected with C70M mutant
cDNA. To this purpose, total RNAs from COS7 cells trans-
fected with wt, C70S and C70M cDNAs were reverse-tran-
scribed using two oligonucleotides present on coding cDNA
(see Section 2); a fragment of the expected size (137 bp) was
ampli¢ed in all samples, demonstrating the presence of the
respective RNAs (data not shown).
3.5. Replacement of the cysteine by a methionine causes
association to BiP
To verify the hypothesized RER retention of C70M mutant
protein, COS cells expressing wt NS, C70S or C70M proteins
were lysed, immunoprecipitated with anti-NS antibody under
non-denaturing conditions and the immunocomplexes, disso-
ciated in denaturing lysis bu¡er, were loaded on a SDS^
PAGE gel. A Western blot analysis was then performed
with a monoclonal antibody recognizing BiP protein (Fig.
3). A signi¢cant amount of Grp94 and Grp78 co-immunopre-
cipitated with the C70M mutant, while a faint band represent-
ing Gpr78 was detected with C70S protein and no band was
visible with the wt enzyme. These results indicate that the
C70M is a misfolded protein that interacts with the molecular
chaperone BiP.
4. Discussion
In this work, we performed site-directed mutagenesis on the
conserved cysteine present in NS, the lysosomal enzyme
whose de¢ciency causes MPS-IIIA [3] ; using site-directed mu-
tagenesis, we replaced cysteine 70 with two di¡erent amino
acids: the serine residue with a hydrophilic hydroxyl group
and the methionine containing a hydrophobic sterically en-
cumbering ring. C70S and C70M mutant proteins were ex-
pressed in COS cells and analyzed for their catalytic proper-
ties and processing; both the cysteine replacements (C70S and
C70M) had a drastic e¡ect on the enzymatic activity, with loss
of catalytic function (Table 1). Similar results have been re-
ported for the Cys91 of N-acetylgalactosamine 4-sulfatase
[19], the Cys84 of iduronate sulfatase [20], the Cys69 of ar-
ylsulfatase A [21], the Cys79 of N-acetylgalactosamine 6-sul-
fate sulfatase [22].
We show that the Cys70 residue of NS was critical also for
enzyme processing and stability; by Western blot analysis it
was possible to detect the 62 kDa precursor and the 56 kDa
mature polypeptides in COS cells transfected either with wt or
with C70S cDNAs, but only a minor amount of precursor
form and no mature form in COS cells transfected with
C70M cDNA. Furthermore, metabolic labeling experiments
demonstrated a decreased amount of mature form for C70S
protein; while a severely impaired biosynthesis of C70M mu-
tant was evident, with neither the mature proteolytically pro-
cessed protein nor any secreted enzyme. Studies performed in
MSD ¢broblasts showed that arylsulfatase A, arylsulfatase B
and steroid sulfatase, although inactive, were normally pro-
cessed [23] ; results obtained from expression studies on the
cysteine 84 mutant of iduronate sulfatase [20] showed that a
C84A mutation had a drastic e¡ect on processing, while C84T
replacement produced a small amount of IDS inactive mature
forms. Experiments performed on the cysteine 91 of N-acetyl-
galactosamine 4-sulfatase showed that the C91T replacement
caused a lower level of intracellular protein [19]; however, a
subsequent study revealed that the C91T was synthesized nor-
mally in the RER where it was apparently retained and de-
graded by the quality control system, but was not processed
[24]. Also in this study, since RT-PCR analysis showed that
the C70M mutant was correctly translated in vitro, the C70M
protein seems to be synthesized but not proteolytically pro-
cessed. The interaction of the C70M mutant with BiP, the
molecular chaperone, suggests that a large part of this mutant
is retained by the RER quality control system.
Previous studies have demonstrated that point mutations
may directly a¡ect the protein function or alter the correct
folding and cause subsequent premature degradation of the
mutant proteins within the RER; the resulting protein mis-
folding has been implicated in the pathogenesis of some ge-
netic diseases [25,26]. The mechanism involved in the degra-
dation of the mutant protein in lysosomal storage disorders
has yet to be fully characterized, but recent evidence indicates
the involvement of the degradation system in the RER quality
control processes [24] ; furthermore, protein conformation
changes have been observed in the mutant 4-sulfatase protein
in patient ¢broblasts [19].
In conclusion, we con¢rm that the cysteine present in the
active site of NS is essential for the catalytic function and
have demonstrated that it is also important for the correct
processing of this enzyme; moreover, the replacement of
this residue may impair the folding and/or the stability of
the protein.
Table 1
NS activity of NS mutants transiently transfected in COS cells
Cell type NS activitya (nmol/17 h/mg) L-Galactosidase activitya (Wmol/h/mg) Normalized NS activityb
Untransfected 4.9 þ 2.0 8.5 þ 2.2 4.9
Wt 58.3 þ 3.3 84.2 þ 4.7 58.3
C70S 7.8 þ 0.9 72.5 þ 2.7 9.0
C70M 8.5 þ 1.0 71.6 þ 5.7 10.0
aValues are the mean þ S.D. of three independent experiments.
bBy comparison of the L-galactosidase activity of the mutants with the L-galactosidase activity of the wt construct, to correct for transfection
variability.
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